Platinum(II) drugs are activated intracellularly by aquation of the leaving groups and then bind to
DNA, forming
DNA adducts capable to activate various signal-transduction pathways. Mostly explored in recent years are Pt(IV) complexes which allow the presence of two additional
ligands in the axial positions suitable for the attachment of other
cancer-targeting
ligands. Here we have extended this strategy by coordinating in the axial positions of
kiteplatin ([PtCl₂(cis-1,4-
DACH)],
DACH = Diaminocyclohexane) and its
CBDCA (1,1-cyclobutanedicarboxylate) analogue the
antioxidant α-
Lipoic acid (ALA), an inhibitor of the mitochondrial
pyruvate dehydrogenase kinase (PDK). The new compounds (cis,trans,cis-[Pt(
CBDCA)(ALA)₂(cis-1,4-
DACH)], 2, and cis,trans,cis-[PtCl₂(ALA)₂(cis-1,4-
DACH)], 3), after intracellular reduction, release the precursor Pt(II) species and two molecules of ALA. The Pt residue is able to target
DNA, while ALA could act on mitochondria as activator of the
pyruvate dehydrogenase complex, thus suppressing anaerobic glycolysis. Compounds 2 and 3 were tested in vitro on a panel of five human
cancer cell lines and compared to
cisplatin,
oxaliplatin, and
kiteplatin. They proved to be much more effective than the reference compounds, with complex 3 most effective in 3D spheroid
tumor cultures. Notably, treatment of human A431
carcinoma cells with 2 and 3 did not determine increase of cellular ROS (usually correlated to inhibition of mitochondrial PDK) and did not induce a significant depolarization of the mitochondrial membrane or alteration of other morphological mitochondrial parameters.